<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intracerebroventricular treatment with redox-regulating Mn(III) N-hexylpyridylporphyrin (MnPorphyrin) is remarkably efficacious in experimental central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) injury </plain></SENT>
<SENT sid="1" pm="."><plain>Clinical development has been arrested because of poor blood-brain barrier penetration </plain></SENT>
<SENT sid="2" pm="."><plain>Mn(III) meso-tetrakis (N-hexylpyridinium-2-yl) <z:chebi fb="2" ids="8337">porphyrin</z:chebi> (MnTnHex-2-PyP) was synthesized to include four six-carbon (<z:chebi fb="0" ids="24593">hexyl</z:chebi>) side chains on the core MnPorphyrin structure </plain></SENT>
<SENT sid="3" pm="."><plain>This has been shown to increase in vitro lipophilicity 13,500-fold relative to the hydrophilic ethyl analog Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)<z:chebi fb="2" ids="8337">porphyrin</z:chebi> (MnTE-2-PyP) </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:mpath ids='MPATH_458'>normal</z:mpath> mice, we found brain MnTnHex-2-PyP accumulation to be ∼9-fold greater than MnTE-2-PyP 24 h after a single intraperitoneal dose </plain></SENT>
<SENT sid="5" pm="."><plain>We then evaluated MnTnHex-2-PyP efficacy in outcome-oriented models of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>For focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, rats underwent 90-min middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Parenteral MnTnHex-2-PyP treatment began 5 min or 6 h after reperfusion <z:hpo ids='HP_0003674'>onset</z:hpo> and continued for 7 days </plain></SENT>
<SENT sid="8" pm="."><plain>Neurologic function was improved with both early (P = 0.002) and delayed (P = 0.002) treatment <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Total <z:mpath ids='MPATH_124'>infarct</z:mpath> size was decreased with both early (P = 0.03) and delayed (P = 0.01) treatment </plain></SENT>
<SENT sid="10" pm="."><plain>MnTnHex-2-PyP attenuated nuclear factor κB nuclear DNA binding activity and suppressed <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-�� and interleukin-6 expression </plain></SENT>
<SENT sid="11" pm="."><plain>For <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo>, mice underwent <z:mpath ids='MPATH_81'>perforation</z:mpath> of the anterior cerebral artery and were treated with intraperitoneal MnTnHex-2-PyP or vehicle for 3 days </plain></SENT>
<SENT sid="12" pm="."><plain>Neurologic function was improved (P = 0.02), and vasoconstriction of the anterior cerebral (P = 0.0005), middle cerebral (P = 0.003), and internal carotid (P = 0.015) arteries was decreased by MnTnHex-2-PyP </plain></SENT>
<SENT sid="13" pm="."><plain>Side-chain elongation preserved MnPorphyrin redox activity, but improved <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> bioavailability sufficient to cause improved outcome from <z:hpo ids='HP_0011009'>acute</z:hpo> <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> injury, despite delay in parenteral treatment <z:hpo ids='HP_0003674'>onset</z:hpo> of up to 6 h </plain></SENT>
<SENT sid="14" pm="."><plain>This advance now allows consideration of MnPorphyrins for treatment of cerebrovascular disease </plain></SENT>
</text></document>